登录 | 注册    关注公众号  
搜索

Complement Component C5a信息

英文名称:C5a anaphylatoxin chemotactic receptor
中文名称:过敏毒素C5a趋化受体
靶点别称:C5AR,Complement Component 5 Receptor 1 (C5a Ligand),C5a Anaphylatoxin Chemotactic Receptor,Complement C5a Receptor 1,C5a Anaphylatoxin Receptor,C5AR1,C5a Anaphylatoxin Chemotactic Receptor 1,Complement Component 5a Receptor 1,C5a Ligand,C5A,C5R1,CD88,CD88 Antigen,Complement Component 5 Receptor 1,Receptor, Anaphylatoxin C5a,C5a-R
上市药物数量:1
临床药物数量:3
最高研发阶段:批准上市

Complement Component C5a产品列表

货号 物种 产品描述 蛋白结构 纯度 活性
 
评论(0)
 

Complement Component C5a 分子别名

C5a,Complement Component 5a

Complement Component C5a 分子背景

Human Complement Component C5a (C5a) is also known as C5,and is a protein fragment released from complement component C5.,is a potent chemotactic factor for human peripheral blood neutrophils and monocytes, and is believed to play an important role in a number of inflammatory conditions. There are several functions in the below: C5a is an anaphylatoxin, causing the release of histamine from mast cells; C5a is effective leukocyte chemoattractants, causing the accumulation of white blood cells, especially neutrophil granulocytes, at sites of complement activation; C5a activates white blood cells by increasing avidity for white blood cell integrins and upregulating the Lipoxygenase pathway for arachidonic acid metabolism; C5a is a powerful inflammatory mediator, and seems to be a key factor in the development of pathology of many inflammatory diseases involving the complement system; C5a modulates balance between activating versus inhibitory IgG Fc receptors on leukocytes, thereby enhancing autoimmune response.

Complement Component C5a 前沿进展

Complement Component C5a上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Avacopan CCX-168 批准上市 Chemocentryx Tavneos, Vynpenta, タブネオスカプセル EU 韦格纳肉芽肿, 显微镜下多血管炎 Vifor Fresenius Medical Care Renal Pharma France Vifor Sa 2021-09-27 韦格纳肉芽肿, 抗中性粒细胞胞浆抗体相关性血管炎, 显微镜下多血管炎 详情

Complement Component C5a临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
TJ-210001 MOR-210; MOR044254; TJ 210; TJ210001; WBP-2191; TJ-210001; TJ-210; MOR-044254 临床一期 Morphosys 实体瘤 详情
AON-D-21 AON-D-21 详情
MP-435 MP-435 Mitsubishi Tanabe Pharma Corp 详情
Avdoralimab NNC-0215-0384; IPH-5401; Anti-C5aR-215; NN-8210 临床二期 诺和诺德制药 实体瘤, 类风湿关节炎, 肿瘤, 冠状病毒感染, 大疱性类天疱疮, 炎性疾病 详情

消息提示

请输入您的联系方式,再点击提交!

确定